Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab (2017)
Fonte: The New England Journal of Medicine. Unidade: FM
Assuntos: COLESTEROL, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO, ANTICORPOS MONOCLONAIS, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIDKER, Paul M. et al. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. The New England Journal of Medicine, v. 376, n. 16, p. 1517-1526, 2017Tradução . . Disponível em: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1614062. Acesso em: 30 set. 2024.APA
Ridker, P. M., Tardif, J. -C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W., et al. (2017). Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. The New England Journal of Medicine, 376( 16), 1517-1526. doi:10.1056/NEJMoa1614062NLM
Ridker PM, Tardif J-C, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab [Internet]. The New England Journal of Medicine. 2017 ; 376( 16): 1517-1526.[citado 2024 set. 30 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1614062Vancouver
Ridker PM, Tardif J-C, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab [Internet]. The New England Journal of Medicine. 2017 ; 376( 16): 1517-1526.[citado 2024 set. 30 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1614062
